Clinical Trial Update: CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 1/2 study using CRISPR-edited HLA donor kidneys to reduce transplant rejection risk, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Kidney Failure
• Kidney Transplant Rejection
• Renal Cell Carcinoma
• Renal Ischemia

Snippet

Sponsor: AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC | Conditions: End-Stage Renal Disease, End Stage Renal Disease on Dialysis | Phase 1, Phase 2 | Status: RECRUITING